IVIg – Introveneous Immunoglobulin
Intravenous immunoglobulin (IVIG) is a blood product administered intravenously. It contains the pooled IgG (immunoglobulin antibody G) extracted from the plasma of over one thousand blood donors. IVIG’s effects last between 2 weeks and 3 months. Read more…
- The hypogammaglobinemia and impaired T-cell function associated with chronic lymphocytic leukemia (CLL) predispose patients to potentially serious infections.
- National Comprehensive Cancer Network recommends IVIG prophylaxis when there are recurrent infections requiring antibiotics or hospitalization and IgG levels are below 500. IVIG is FDA indicated for CLL. For Chronic lymphocytic leukemia the recommended dose is 0.3-0.6 mg/kg every 3-4 weeks. Read more..
Prophylaxis Against Infections with Low-dose IVIG
– still not cost-effective
SCIg – Subcutaneous Immunoglobulin
Unlike intravenous administration, which infuses medication into a vein, subcutaneous therapy uses a small needle that is inserted into the tissue just below the surface of the skin in one or more areas of the body (such as the stomach, thigh, upper arm, or hip). A small, portable pump controls the amount and rate of the infusion. With physician’s approval, patients or caregivers are able to administer therapy themselves,.. Read more…
[to be developed further]
Since the 1990s, no transmission of infectious diseases have been reported from U.S.-licensed IVIG products.